Cellerys will start a multi-center phase IIa trial in 2022 as the next important milestone to bring RED4MS to patients.RED4MS is a unique approach to treat and prevent multiple sclerosis (“MS”). It has been developed over the past decade and has successfully passed phase Ib clinical testing.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2015
  • Number of employees in Switzerland
    10-19
Key business